Bibliography
- Van Dam D, De Deyn PP. Drug discovery in dementia: the role of rodent models. Nat Rev Drug Discov 2006;5:965-70
- Jellinger KA. Significance of brain lesions in Parkinson disease dementia and Lewy body dementia. Frontiers Neurol Neurosci 2009;24:114-25
- Browne SE, Beal MF. Oxidative damage in Huntington's disease pathogenesis. Antioxid Redox Signal 2006;8:2061-73
- Phukan J, Pender NP, Hardiman O. Cognitive impairment in amyotrophic lateral sclerosis. Lancet Neurol 2007;6:994-1003
- Joyce EM, Roiser JP. Cognitive heterogeneity in schizophrenia. Curr Opin Psychiat 2007;20:268-72
- Thomas AJ, O'Brien JT. Depression and cognition in older adults. Curr Opin Psychiat 2008;21:8-13
- Skirrow C, McLoughlin G, Kuntsi J, Asherson P. Behavioral, neurocognitive and treatment overlap between attention-deficit/hyperactivity disorder and mood instability. Expert Rev Neurotherapeut 2009;9(4):489-503
- Grenard JL, Ames SL, Wiers RW, Working memory capacity moderates the predictive effects of drug-related associations on substance use. Psychology Addict Behav 2008;22:426-32
- Taggart DP, Westaby S. Neurological and cognitive disorders after coronary artery bypass grafting. Curr Opin Cardiol 2001;16:271-6
- Poggesi A, Pantoni L. Investigations in primary care. Front Neurol Neurosci 2009;24:66-78
- Silver JM, McAllister TW, Arciniegas DB. Depression and cognitive complaints following mild traumatic brain injury. Am J Psychiat 2009;166:653-61
- Salthouse TA. When does age-related cognitive decline begin? Neurobiol Aging 2009;30:507-14
- Mariani E, Monastero R, Mecocci P. Mild cognitive impairment: a systematic review. J Alzheimers Dis 2007;12:23-35
- Terry AV Jr, Buccafusco JJ. The cholinergic hypothesis of Alzheimer's disease: recent challenges and their implications for novel drug development. J Pharmacol Exp Ther 2003;306:821-7
- Pepeu G, Giovannini MG. Cholinesterase inhibitors and beyond. Curr Alzheimer Res 2009;6:86-96
- Reisberg B, Doody R, Stöffler A, Memantine study group. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003;348:1333-41
- Buccafusco JJ, Terry AVJr. Donepezil-induced improvement in delayed matching accuracy by young and old rhesus monkeys. J Mol Neurosci 2004;24:85-91
- Nordberg A, Darreh-Shori T, Peskind E, Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients. Curr Alzheimer Res 2009;6:4-14
- Coyle JT, Geerts H, Sorra K, Amatniek J. Beyond in vitro data: a review of in vivo evidence regarding the allosteric potentiating effect of galantamine on nicotinic acetylcholine receptors in Alzheimer's neuropathology. J Alzheimers Dis 2007;11:491-507
- Buccafusco JJ. Multifunctional receptor-directed drugs for disorders of the central nervous system. Neurotherapeutics 2009;6:4-13
- Melnikova I. Therapies for Alzheimer's disease. Nat Rev Drug Discov 2007;6:341-2
- Kozikowski IP, Gaisina IN, PetukhovHighly PA, Highly potent and specific GSK-3 inhibitors that block tau phosphorylation and decrease α-synuclein protein expression in a cellular model of Parkinson's disease. Chem Med Chem 2006;1:256-66
- Wischik CM, Edwards PC, Lai RYK. Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc Natl Acad Sci USA 1996;93:11213-8
- Hooper NM, Turner AJ. The search for alpha-secretase and its potential as a therapeutic approach to Alzheimer s disease. Curr Med Chem 2002;9:1107-19
- Suzuki T, Hide I, Matsubara A, Microglial alpha7 nicotinic acetylcholine receptors drive a phospholipase C/IP3 pathway and modulate the cell activation toward a neuroprotective role. J Neurosci Res 2006;83:1461-70
- Li XD, Arias E, Jonnala RR, Effect of amyloid peptides on the increase in TrkA receptor expression induced by nicotine in vitro and in vivo. J Mol Neurosci 2005;27:325-36
- Lee GM, Craik CS. Trapping moving targets with small molecules. Science 2009;24:213-5
- Conn PJ, Christopoulos A, Lindsley CW. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat Rev Drug Discov 2009;8:41-54
- Ross DA, Lee S, Reiser V, Multiplexed assays by high-content imaging for assessment of GPCR activity. J Biomol Screening 2008;13:449-55
- Klein J. Phenserine. Expert Opin Invest Drugs 2007;16:1087-97
- Buccafusco JJ. Neuronal nicotinic receptor subtypes: defining therapeutic targets. Mol Interventions 2004;4:285-95
- Parkinson Study Group. Randomized placebo-controlled study of the nicotinic agonist SIB-1508Y in Parkinson disease. Neurology 2006;66:408-10
- Ren K, Puig V, Papke RL, Multiple calcium channels and kinases mediate alpha7 nicotinic receptor neuroprotection in PC12 cells. J Neurochem 2005;94:926-33
- Picciotto MR, Zoli M. Neuroprotection via nAChRs: the role of nAChRs in neurodegenerative disorders such as Alzheimer's and Parkinson's disease. Frontiers Biosci 2008;13:492-504
- Marrero MB, Bencherif M. Convergence of alpha 7 nicotinic acetylcholine receptor-activated pathways for anti-apoptosis and anti-inflammation: central role for JAK2 activation of STAT3 and NF-kappaB. Brain Res 2009;1256:1-7
- Olincy A, Harris JG, Johnson LL, Proof-of-concept trial of an alpha 7 nicotinic agonist in schizophrenia. Arch Gen Psychiat 2006;63:630-8
- Terry AV Jr, Buccafusco JJ, Wilson C. Cognitive dysfunction in neuropsychiatric disorders: selected serotonin receptor subtypes as therapeutic targets. Behav Brain Res 2008;195:30-8
- Upton N, Chuang TT, Hunter AJ, Virley DJ. 5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer's disease. Neurotherapeutics 2008;5:458-69
- Cho S, Hu Y. Activation of 5-HT4 receptors inhibits secretion of β-amyloid peptides and increases neuronal survival. Exp Neurol 2007;203:274-8
- Berezhnoy D, Gravielle MC, Farb DH. Pharmacology of the GABAA Receptor. In: Sibley DR, Hanin I, Kuhar M, Skolnick P, editors, Handbook of Contmporary Neuropharmacology, Hoboken NJ: John Wiley & Sons; 2007. p. 465-568
- Lewis DA, Cho RY, Carter CS, Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia. Am J Psychiat 2008;165:1585-93
- Gassmann M, Bettler B. Metabotropic GABA receptors. In: Sibley DR, Hanin I, Kuhar M, Skolnick P, editors, Handbook of contmporary neuropharmacology, Hoboken NJ: John Wiley & Sons; 2007. p. 569-615
- Froestl W, Gallagher M, Jenkins H, SGS742: the first GABA(B) receptor antagonist in clinical trials. Biochem Pharmacol 2004;68:1479-87
- Youdim MBH, Buccafusco JJ. Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacological Sci 2005;26:27-35
- Bachurin S, Bukatina E, Lermontova N, Antihistamine agent Dimebon as a novel neuroprotector and a cognition enhancer. Ann NY Acad Sci 2001;939:425-35
- Lermontova NN, Redkozubov AE, Shevtsova EF, Dimebon and tacrine inhibit neurotoxic action of beta-amyloid in culture and block L-type Ca(2+) channels. Bull Exp Biol Med 2001;132:1079-83
- Bachurin SO, Shevtsova EP, Kireeva EG, Mitochondria as a target for neurotoxins and neuroprotective agents. Ann NY Acad Sci 2003;993:334-44
- Doody RS, Gavrilova SI, Sano M, Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet 2008;372:207-15
- Hancock AA, Fox GB. Perspectives on cognitive domains, H3 receptor ligands and neurological disease. Expert Opin Investig Drugs 2004;13:1237-48
- Albuquerque EX, Santos MD, Alkondon M, Modulation of nicotinic receptor activity in the central nervous system: a novel approach to the treatment of Alzheimer disease. Alzheimer Dis Assoc Disord 2001;15(Suppl 1):S19-25
- Coyle JT, Geerts H, Sorra K, Amatniek J. Beyond in vitro data: a review of in vivo evidence regarding the allosteric potentiating effect of galantamine on nicotinic acetylcholine receptors in Alzheimer's neuropathology. J Alzheimers Dis 2007;11:491-507
- Hurst RS, Hajós M, Raggenbass M, A novel positive allosteric modulator of the α7 neuronal nicotinic acetylcholine receptor: in vitro and in vivo characterization. J Neurosci 2005;25:4396-405
- Gronlien JH, Hakerud M, Ween H, Distinct profiles of alpha7 nAChR positive allosteric modulation revealed by structurally diverse chemotypes. Mol Pharmacol 2007;72:715-24
- Livingstone PD, Srinivasan J, Kew JN, alpha7 and non-alpha7 nicotinic acetylcholine receptors modulate dopamine release in vitro and in vivo in the rat prefrontal cortex. Eur J Neurosci 2009;29:539-50
- Sood A, Beach JW, Webster SJ, The effects of JWB1-84-1 on memory-related task performance by amyloid Aβ transgenic mice and by young and aged monkeys. Neuropharmacology 2007;53:588-600
- Buccafusco JJ, Beach WJ, Terry AVJr. Desensitization of nicotinic acetylcholine receptors as a strategy for drug development. J Pharmacol Exp Ther 2009;328:364-70
- Gardoni F, Di Luca M. New targets for pharmacological intervention in the glutamatergic synapse. Eur J Pharmacol 2006;545:2-10
- Chappell AS, Gonzales C, Williams J, AMPA potentiator treatment of cognitive deficits in Alzheimer disease. Neurology 2007;68:1008-12
- Guan JS, Haggarty SJ, Giacometti E, HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 2009;459:55-63
- Hahnen E, Hauke J, Tränkle C, Histone deacetylase inhibitors: possible implications for neurodegenerative disorders. Expert Opin Investig Drugs 2008;17:169-84
- Wei J, Walton EA, Milici A, Buccafusco JJ. m1-m5 Muscarinic receptor distribution in rat CNS by RT-PCR and HPLC. J Neurochem 1994;63:815-21
- Flynn DD, Ferrari-DiLeo G, Levey AI, Mash DC. Differential alterations in muscarinic receptor subtypes in Alzheimer's disease: Implications for cholinergic-based therapies. Life Sci 1995;56:869-76
- Mehta MA. Riedel WJ. Dopaminergic enhancement of cognitive function. Curr Pharmaceut Design 2006;12:2487-500
- Renerkens OAH, Rutten K, Steinbusch HSM, Selective phosphodiesterase inhibitors: a promising target for cognition enhancement. Psychopharmacology 2009;202:419-43
- Haile M, Limson F, Gingrich K, Nimodipine prevents transient cognitive dysfunction after moderate hypoxia in adult mice. J Neurosurg Anesthesiol 2009;21:140-4
- Winblad B, Fioravanti M, Dolezal T, Therapeutic use of nicergoline. Clin Drug Investig 2008;28:533-52
- Schaeffer EL, Forienza OV, Gattaz WF. Phospholipase A2 activation as a therapeutic approach for cognitive enhancement in early-stage Alzheimer's disease. Psychopharmacology 2009;202:37-51
- Gastambide F, Viollet C, Lepousez G, Hippocampal SSTR4 somatostatin receptors control the selection of memory strategies. Psychopharmacology 2009;202:153-63
- Gasbarri A, Pompili A, D'Onofrio A, Working memory for emotional facial expressions: role of estrogen in humans and non-human primates. Rev Neurosci 2008;19:129-48
- Black MD, Varty GB, Arad M, Procognitive and antipsychotic efficacy of glycine transport 1 inhibitors (GlyT1) in acute and neurodevelopmental models of schizophrenia: latent inhibition studies in the rat. Psychopharmacology 2009;202:385-96
- Lim WK. GPCR drug discovery: novel ligands for CNS receptors. Recent Patents CNS Drug Discov 2007;2:107-12
- Huentelman MJ, Stephan DA, Talboom J, Peripheral delivery of a ROCK inhibitor improves learning and working memory. Behav Neurosci 2009;123:218-23
- Gard PR, Rusted JM. Angiotensin and Alzheimer's disease: therapeutic prospects. Expert Rev Neurotherapeut 2004;4:87-96
- Gard PR. Angiotensin as a target for the treatment of Alzheimer's disease, anxiety and depression. Expert Opin Invest Drugs 2004;8:7-14
- Hajduk PJ, Greer J. A decade of fragment-based drug design: strategic advances and lessons learned. Nat Rev Drug Discov 2007;6:211-9
- Keseru GM, Makara GM. The influence of lead discovery strategies on the properties of drug candidates. Nat Rev Drug Discov 2009;8:203-12
- Enna SJ, Williams M. Challenges in the search for drugs to treat central nervous system disorders. J Pharmacol Exp Ther 2009;329:404-11
- Faghih R, Gopalakrishnan M, Briggs CA. Allosteric modulators of the α7 nicotinic acetylcholine receptor. J Med Chem 2008;51:701-12
- Buccafusco JJ, Terry AVJr. Multiple CNS targets for eliciting beneficial effects on memory and cognition. J Pharmacol Exp Ther 2000;295:438-46